Finance

Lists
Q3 2026 earnings • released • EPS miss -26.00% • Revenue beat +3.08%
See results
AUTL:NASDAQ
Autolus Therapeutics PLC
$1.17
-1.68%
(-0.020) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AUTL...
Open
$1.20
High
$1.24
Low
$1.16
Mkt. cap
311.62M
Avg. vol.
2.38M
Volume
1.80M
52-wk high
$2.58
52-wk low
$1.12
EPS
-$0.96
Beta
2.32
Shares outstanding
266.34M
No. of employees
753
Open
$1.20
High
$1.24
Low
$1.16
Mkt. cap
311.62M
Avg. vol.
2.38M
Volume
1.80M
52-wk high
$2.58
52-wk low
$1.12
EPS
-$0.96
Beta
2.32
Shares outstanding
266.34M
No. of employees
753
News stories
From web sources and news partners
About Autolus Therapeutics PLC
CEOChristian Itin
Employees753
Founded2014
Headquarters-
SectorHealth Care
IndustryBiotechnology
Analyst ratings
Based on 4 analysts giving stock ratings to AUTL in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for AUTL in the last 3 months.
Highest
Current $1.17
$10.00 (+754.70%)
Average
$8.33 (+611.97%)
Lowest
$5.00 (+327.35%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Maintained
$10.00
+754.7%
11/11/2026
Unknown Analyst
Wells Fargo
Buy
Maintained
$5.00
+327.4%
11/11/2026
Emily Bodnar
H.C. Wainwright
Buy
Initiated
$10.00
+754.7%
11/02/2026
Gil Blum
Needham
Buy
Maintained
$10.00
+754.7%
10/02/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
09/25/2026
Rajan Sharma
Goldman Sachs
Buy
Reiterated
$5.80
+395.7%
08/11/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$10.00
+754.7%
06/10/2026
Unknown Analyst
Goldman Sachs
Buy
Reiterated
$5.40
+361.5%
05/15/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
-$0.21 / -$0.17
-26.00%miss
Revenue / Est. (USD)
41.24M / 40.01M
+3.08%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
24.29M
26.22M
45.69M
41.24M
Cost of goods sold
54.29M
45.78M
48.37M
17.93M
Cost of revenue
54.29M
45.78M
48.37M
17.93M
Research and development expenses
-
-
-
30.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
42.12M
39.95M
41.16M
35.95M
Operating expense
42.12M
39.95M
41.16M
66.85M
Total operating expenses
96.41M
85.73M
89.53M
84.77M
Operating income
-72.12M
-59.51M
-43.84M
-43.54M
Other non operating income
-11.66M
100.00K
15.35M
-
EBT including unusual items
-91.52M
-70.74M
-38.65M
-55.58M
EBT excluding unusual items
-91.17M
-70.74M
-38.65M
-55.58M
Income tax expense
-1.18M
863.00K
465.00K
-489.00K
Effective tax rate
1.29%
-1.22%
-1.20%
0.88%
Other operating expenses
-
-
-
-
Net income
-90.33M
-71.60M
-39.11M
-55.09M
Net profit margin
-371.90%
-273.09%
-85.60%
-133.59%
Earnings per share
-0.34
-0.27
-0.15
-0.21
Interest and investment income
3.23M
2.47M
1.88M
-
Interest expense
-11.01M
-11.12M
-12.50M
-
Net interest expenses
-7.78M
-8.66M
-10.62M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-69.49M
-56.81M
-41.19M
-40.88M
Gain or loss from assets sale
11.00K
2.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps